ROBERTS BRIAN KENNETH Insider Trading Activity

Average Profitability
98.57%
Insider Buys Quantity
11
Insider Buys Sum
$183,943.84
Insider Sells Quantity
0
Insider Sells Sum
$0

Insider Activity of ROBERTS BRIAN KENNETH

According to the SEC Form 4 filings, ROBERTS BRIAN KENNETH, being in a position of

  1. Chief Medical Officer at Rezolute, Inc.,
    оver the last 12 months, has bought 28000 shares for $47,600, and sold 0 shares,
    over all time since 2022-05-04, has bought 97952 shares for $242,483, and sold 0 shares.

Biography of ROBERTS BRIAN KENNETH

No biography is available at this moment.

Statistics of Insider Transactions Last Year

Amount of Insider Buys and Sells by Stocks

Buys
$47,6001100
Sells
$000

Comparison of Insiders on Amount of Buys and Sells

2025-12-16PurchaseRezolute, Inc.
RZLT
Chief Medical Officer
28,000
0.0254%
$1.70$47,600+79.7%
2025-06-25PurchaseRezolute, Inc.
RZLT
Chief Medical Officer
2,500
0.0029%
$4.38$10,9390%
2024-06-14PurchaseRezolute, Inc.
RZLT
Chief Medical Officer
7,600
0.0139%
$3.91$29,743+14.68%
2024-05-23PurchaseRezolute, Inc.
RZLT
Chief Medical Officer
7,500
0.0164%
$2.69$20,138+50.49%
2024-03-28PurchaseRezolute, Inc.
RZLT
Chief Medical Officer
500
0.0013%
$2.55$1,275+80.59%
2024-03-14PurchaseRezolute, Inc.
RZLT
Chief Medical Officer
10,000
0.024%
$1.88$18,800+153.02%
2024-03-07PurchaseRezolute, Inc.
RZLT
Chief Medical Officer
500
0.0013%
$1.85$925+154.42%
2024-02-26PurchaseRezolute, Inc.
RZLT
Chief Medical Officer
2,000
0.0052%
$1.70$3,400+180.49%
2024-02-23PurchaseRezolute, Inc.
RZLT
Chief Medical Officer
6,000
0.015%
$1.69$10,140+168.02%
2024-02-16PurchaseRezolute, Inc.
RZLT
Chief Medical Officer
7,000
0.0171%
$1.31$9,142+240.74%
2023-07-03PurchaseRezolute, Inc.
RZLT
Chief Medical Officer
5,000
0.0091%
$1.90$9,500-27.59%
2022-05-17PurchaseRezolute, Inc.
RZLT
Sr VP, Clinic Development
300
0.0014%
$2.95$884-31.34%
2022-05-04PurchaseRezolute, Inc.
RZLT
Sr VP, Clinic Development
21,052
0.1166%
$3.80$79,998-36.6%
Total: 13
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.